Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.67 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icrf-193 SCHEMBL14006976 | 0.81 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL27318121 | 0.81 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL729019 | 0.81 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL438498 | 0.81 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL9846833 | 0.80 | TOP2A (0.60) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL20158971 | 0.78 | TOP2A (0.66) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL3683167 | 0.75 | TOP2A (0.58) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL14006912 | 0.72 | TOP2A (0.65) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL728997 | 0.72 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL13857354 | 0.72 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524851-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | claimed |
| US-9468613-B2 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | TOSK, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150258046-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOSK, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9061038-B2 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | TOSK, INCORPORATED (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2242360-B1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20120329744-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOSK, INCORPORATED | 2012-12-27 | — | — | US | disclosed |
| US-8227517-B2 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | TOSK, INCORPORATED (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20090325893-A1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-1991000729-A2 | BIS-DIOXOPIPERAZINES, AND THEIR USE AS PROTECTING AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-01-24 | — | — | WO | disclosed |
| EP-0409499-A2 | Pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329744-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885ALDH1A1 2086/4885 |
| US-20150258046-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885ALDH1A1 2086/4885 |
| US-20090325893-A1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885ALDH1A1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.